Meta-analysis about Western Medicine combined with activating blood drugs on modulating blood glucose and lipids in diabetic patients  

作　　者：黄苏萍 邱彩霞 林妙娴 陈龙辉 颜群芳 陈超云 王思梅 叶梦捷 郑沪琳 康文倩 黄博威 衡先培 

机构地区：[1]Fujian University of Traditional Chinese Medicine,Fuzhou 350122,China [2]The People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine,Fuzhou 350004,China [3]Xiamen Heshan Street Community Health Service Center,Xiamen 361015,China [4]Pi-Wei Institute,Guangzhou University of Chinese Medicine,Guangzhou 510405,China

出　　处：《World Journal of Integrated Traditional and Western Medicine》2016年第3期8-14,共7页世界中西医结合杂志（英文）

基　　金：Natural Science Foundation of China(81173179);Major project of Fujian Science and technology(2014Y0063);Natural Science Foundation of Fujian Province(2012J01392)

摘　　要：OBJECTIVE： To assess the effect of activating blood drugs （AB drugs） on blood glucose and lipid levels of diabetic patients METHODS： Systematic searches were conducted on 6 electronic databases and the search time was cut off in May 2016. Randomized controlled trials （RCTs） were included if they investigated diabetic patients who received Western medicine combined withAB drugs in the experimental groups and solitary usage of corresponding Western medicine or placebo in the control groups. 6 outcome measures, which were considered as inclusion, were changes in fasting blood glucose （FBG）, glycosylated haemoglobin A1 c （HbA 1 c）, total triglyceride （TG）, total cholesterol （TC）, low density lipoprotein cholesterol （LDL-c） and high density lipoprotein cholesterol （HDL-c）. The literature quality was assessed by Cochrane score for risk of bias in Review Manager 5.2, as well as meta-analysis was performed. RESULTS： 7 RCTs comprising 999 patients met all inclusion criteria. Meta-analysis showed beneficial effects of Western medicine combined with AB drugs on modulating FBG, TC, LDL-c and HDL-c compared with Western medicine or placebo （P〈0.05）, while no difference was observed in HbAlc, and TG （P〉0.05）. To some extent, the therapeutic effects of Western medicine combined with AB drugs were better than that of solitary usage of Western medicine or placebo. Besides, AB drugs were safe and reliable with little toxic and side-effects. CONCLUSIONS： The meta-analysis suggests beneficial effects of Western medicine combined with AB drugs on modulating blood glucose and lipids in diabetic patients.OBJECTIVE:To assess the effect of activating blood drugs(AB drugs) on blood glucose and lipid levels of diabetic patients.METHODS:Systematic searches were conducted on 6 electronic databases and the search time was cut off in May 2016.Randomized controlled trials(RCTs) were included if they investigated diabetic patients who received Western medicine combined with AB drugs in the experimental groups and solitary usage of corresponding Western medicine or placebo in the control groups.6 outcome measures,which were considered as inclusion,were changes in fasting blood glucose(FBG),glycosylated haemoglobin A1 c(HbA1c),total triglyceride(TG),total cholesterol(TC),low density lipoprotein cholesterol(LDL-c) and high density lipoprotein cholesterol(HDL-c).The literature quality was assessed by Cochrane score for risk of bias in Review Manager 5.2,as well as meta-analysis was performed.RESULTS:7 RCTs comprising 999 patients met all inclusion criteria.Meta-analysis showed beneficial effects of Westernmedicine combined with AB drugs on modulating FBG,TC,LDL-c and HDL-c compared with Western medicine or placebo(P<0.05),while no difference was observed in HbA1c,and TG(P>0.05).To some extent,the therapeutic effects of Western medicine combined with AB drugs were better than that of solitary usage of Western medicine or placebo.Besides,AB drugs were safe and reliable with little toxic and side-effects.CONCLUSIONS:The meta-analysis suggests beneficial effects of Western medicine combined with AB drugs on modulating blood glucose and lipids in diabetic patients.

关 键 词：Diabetes mellitus Activating blood drugs Chinese herbal medicine Blood glucose Blood lipid System evaluation 

分 类 号：R587.1[医药卫生—内分泌]